SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study

Frontiers in Oncology

Oncology

Carolyn A. Michaels¹  William L. Greene¹  Elizabeth G. Swift¹  Anita Max¹  Diego R. Hijano²  Jose A. Ferrolino²  Ronald H. Dallas²  Hana Hakim²  Joshua Wolf³  Ted H. Morton⁴  Randall T. Hayden⁵  Shane J. Cross⁶  Julie L. Richardson⁶ 

[1] Center for Advanced Practice Providers, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, United States;Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pathology, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children Research Hospital, Memphis, TN, United States;

关键词: coronavirus;    immunocompromised;    cancer;    hematopoietic cell transplant;    monoclonal antibodies;   

DOI  :  10.3389/fonc.2023.1229655

 received in 2023-05-26, accepted in 2023-07-10,  发布年份 2023

来源: Frontiers

【 摘 要 】

From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28–135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.

【 授权许可】

Unknown   
Copyright © 2023 Hijano, Ferrolino, Swift, Michaels, Max, Hayden, Wolf, Dallas, Greene, Richardson, Hakim, Morton and Cross